Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity.
EP receptor
angiogenesis
cancer-related inflammation
immunosuppression
metastasis
prostaglandin E2
tumor inflammation
tumor microenvironment
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
30
10
2020
revised:
27
11
2020
accepted:
29
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
12
2020
Statut:
epublish
Résumé
The involvement of inflammation in cancer progression has been the subject of research for many years. Inflammatory milieu and immune response are associated with cancer progression and recurrence. In different types of tumors, growth and metastatic phenotype characterized by the epithelial mesenchymal transition (EMT) process, stemness, and angiogenesis, are increasingly associated with intrinsic or extrinsic inflammation. Among the inflammatory mediators, prostaglandin E2 (PGE2) supports epithelial tumor aggressiveness by several mechanisms, including growth promotion, escape from apoptosis, transactivation of tyrosine kinase growth factor receptors, and induction of angiogenesis. Moreover, PGE2 is an important player in the tumor microenvironment, where it suppresses antitumor immunity and regulates tumor immune evasion, leading to increased tumoral progression. In this review, we describe the current knowledge on the pro-tumoral activity of PGE2 focusing on its role in cancer progression and in the regulation of the tumor microenvironment.
Identifiants
pubmed: 33271839
pii: biology9120434
doi: 10.3390/biology9120434
pmc: PMC7760298
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : Progetto Dipartimento di Eccellenza 2018-2022
Organisme : Fondazione Umberto Veronesi
ID : none
Organisme : Fondi FRG 2019
ID : Università di Pavia
Références
J Exp Ther Oncol. 2008;7(4):299-312
pubmed: 19227010
Cancer Res. 2008 Oct 1;68(19):7750-9
pubmed: 18829529
Int J Mol Sci. 2019 Dec 11;20(24):
pubmed: 31835815
Cell Mol Immunol. 2015 Jan;12(1):66-76
pubmed: 24769795
Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862
pubmed: 31477558
Cancer Res. 2020 Jul 1;80(13):2874-2888
pubmed: 32265223
Hepatology. 1999 Mar;29(3):688-96
pubmed: 10051469
Eur J Pharmacol. 2011 Mar 11;654(3):258-65
pubmed: 21185823
Int J Oncol. 2013 Mar;42(3):1093-104
pubmed: 23338277
Cancer Causes Control. 2011 May;22(5):803-10
pubmed: 21409528
J Pathol. 2006 Feb;208(3):356-63
pubmed: 16353170
Iran J Pharm Res. 2011 Fall;10(4):655-83
pubmed: 24250402
J Transl Med. 2013 Feb 04;11:30
pubmed: 23379575
Lancet. 2011 Jan 1;377(9759):31-41
pubmed: 21144578
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Biol Chem. 2008 Jan 25;283(4):2139-46
pubmed: 18042549
Cancer Res. 2007 May 1;67(9):4507-13
pubmed: 17483367
Circ Res. 2009 Sep 25;105(7):657-66
pubmed: 19713533
Oncotarget. 2016 Aug 30;7(35):57077-57085
pubmed: 27494851
Prostaglandins Other Lipid Mediat. 2019 Oct;144:106338
pubmed: 31100474
Cell Mol Immunol. 2013 May;10(3):213-21
pubmed: 23524652
Br J Cancer. 2018 Jan;118(2):213-223
pubmed: 29123257
Prostaglandins Other Lipid Mediat. 2013 Oct;106:99-105
pubmed: 23624019
Am J Transl Res. 2020 Mar 15;12(3):1096-1113
pubmed: 32269737
Oncol Rep. 2014 Dec;32(6):2477-84
pubmed: 25333935
Biochim Biophys Acta. 2012 Sep;1821(9):1224-34
pubmed: 22728329
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncogene. 2012 Jul 19;31(29):3457-66
pubmed: 22081067
Inflamm Regen. 2017 Mar 1;37:4
pubmed: 29259703
Semin Immunopathol. 2017 Feb;39(2):153-163
pubmed: 27456849
Oncotarget. 2017 May 9;8(19):31270-31287
pubmed: 28415726
Ann Epidemiol. 2015 Mar;25(3):183-7
pubmed: 25523895
Oncotarget. 2015 Oct 20;6(32):33500-11
pubmed: 26378024
J Biol Chem. 2015 Dec 11;290(50):29781-93
pubmed: 26475855
Ann Oncol. 2012 Apr;23(4):1053-60
pubmed: 21828376
Biochem Biophys Res Commun. 2014 Sep 5;451(4):587-91
pubmed: 25128827
BMC Gastroenterol. 2014 Jan 02;14:1
pubmed: 24383454
Cancer Res. 2003 May 1;63(9):2330-4
pubmed: 12727858
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s25-32
pubmed: 18174450
Immunity. 2016 Dec 20;45(6):1177-1179
pubmed: 28002722
J Am Coll Cardiol. 2016 Aug 30;68(9):967-76
pubmed: 27561771
BMC Cancer. 2014 Jun 02;14:391
pubmed: 24890520
J Clin Invest. 2018 Jul 2;128(7):2732-2742
pubmed: 29733297
Cancer Res. 2013 Jul 1;73(13):3877-87
pubmed: 23633486
Front Immunol. 2019 Apr 24;10:847
pubmed: 31068935
Lancet Oncol. 2012 May;13(5):518-27
pubmed: 22440112
J Biol Chem. 2004 Nov 5;279(45):46700-5
pubmed: 15347673
Cancer Immunol Res. 2016 May;4(5):400-11
pubmed: 26928462
Cancer Res. 2005 Jun 1;65(11):4496-9
pubmed: 15930264
Hum Pathol. 2013 Aug;44(8):1681-7
pubmed: 23791007
J Immunol Res. 2018 Apr 4;2018:5808962
pubmed: 29850633
J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):13-7
pubmed: 18514508
Clin Cancer Res. 2010 Aug 15;16(16):4207-16
pubmed: 20682710
BMC Cancer. 2017 Nov 14;17(1):763
pubmed: 29137605
Hum Pathol. 2017 May;63:120-127
pubmed: 28300577
Front Immunol. 2018 Aug 09;9:1859
pubmed: 30140269
Am J Cancer Res. 2019 Jun 01;9(6):1145-1160
pubmed: 31285948
Gut. 2006 Jan;55(1):115-22
pubmed: 16118353
Cancer Prev Res (Phila). 2020 Oct;13(10):877-888
pubmed: 32718943
Eur J Pharmacol. 2015 Dec 15;769:127-33
pubmed: 26548623
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106383
pubmed: 31698145
Cancer Res. 1995 Sep 1;55(17):3785-9
pubmed: 7641194
Breast Cancer Res Treat. 2009 Aug;116(3):501-8
pubmed: 19020973
Nitric Oxide. 2017 Jun 1;66:17-29
pubmed: 28257996
Anticancer Res. 2006 Jul-Aug;26(4B):2857-61
pubmed: 16886605
Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):48-58
pubmed: 15967161
Cancer Cell. 2016 Jul 11;30(1):108-119
pubmed: 27374223
Carcinogenesis. 2003 May;24(5):985-90
pubmed: 12771044
Genomics. 1997 Mar 15;40(3):425-34
pubmed: 9073510
Carcinogenesis. 2005 Feb;26(2):353-7
pubmed: 15564292
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
Cancer Prev Res (Phila). 2011 Jul;4(7):984-93
pubmed: 21733822
BMC Cancer. 2018 Apr 10;18(1):402
pubmed: 29636012
Cell Immunol. 2013 Jan;281(1):62-7
pubmed: 23454682
Cancer Res. 2011 Apr 1;71(7):2664-74
pubmed: 21324923
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9409-13
pubmed: 19470469
J Immunother. 2012 Feb-Mar;35(2):179-88
pubmed: 22306906
Gastroenterology. 2020 Mar;158(4):971-984.e10
pubmed: 31734182
J Biol Chem. 2007 Apr 20;282(16):11613-7
pubmed: 17329241
J Immunol. 2011 Aug 1;187(3):1157-65
pubmed: 21709158
Eur J Cancer Prev. 2016 Jul;25(4):259-68
pubmed: 26067033
Oncotarget. 2016 Jul 12;7(28):44350-44364
pubmed: 27322147
Cancer Manag Res. 2018 Oct 26;10:4653-4667
pubmed: 30464589
Mol Carcinog. 2007 Nov;46(11):912-23
pubmed: 17427962
PLoS One. 2016 Apr 20;11(4):e0152402
pubmed: 27096951
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):435-42
pubmed: 20142241
Helicobacter. 2018 Sep;23 Suppl 1:e12518
pubmed: 30203589
Oncol Rep. 2005 Apr;13(4):559-83
pubmed: 15756426
Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26
pubmed: 26712086
Curr Oncol Rep. 2017 Jul;19(7):48
pubmed: 28597105
J Exp Med. 2019 Feb 4;216(2):419-427
pubmed: 30683736
Cancer Lett. 2000 Aug 1;156(1):57-61
pubmed: 10840160
Cancer Prev Res (Phila). 2010 Feb;3(2):148-59
pubmed: 20103722
Cancer Epidemiol. 2015 Dec;39(6):1015-22
pubmed: 26590503
J Invest Dermatol. 2006 Jan;126(1):205-11
pubmed: 16417238
Gastroenterology. 2006 Dec;131(6):1674-82
pubmed: 17087947
FASEB J. 1998 Sep;12(12):1063-73
pubmed: 9737710
Breast Cancer Res Treat. 2015 Feb;150(1):199-207
pubmed: 25677744
Cancer Med. 2020 Apr;9(7):2535-2550
pubmed: 31994315
Clin Cancer Res. 2014 Aug 1;20(15):4096-106
pubmed: 24907113
Nat Med. 2002 Mar;8(3):289-93
pubmed: 11875501
J Immunol. 2007 Jun 1;178(11):6867-75
pubmed: 17513735
Cancer Res. 2002 Mar 15;62(6):1676-81
pubmed: 11912139
Med Oncol. 2013;30(3):663
pubmed: 23873014
Cancer Res. 2002 Jan 15;62(2):403-8
pubmed: 11809688
Lancet Oncol. 2007 Oct;8(10):912-20
pubmed: 17881290
Cancer Res. 1999 Oct 15;59(20):5093-6
pubmed: 10537280
Lancet Oncol. 2009 May;10(5):501-7
pubmed: 19410194
Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5668-5676
pubmed: 29272001
Breast Cancer Res Treat. 2009 Sep;117(2):235-42
pubmed: 18792778
Head Neck. 2019 May;41(5):1220-1226
pubmed: 30537085
Cancer Immunol Immunother. 2011 Nov;60(11):1577-86
pubmed: 21681369
PLoS One. 2018 Aug 22;13(8):e0199014
pubmed: 30133455
Pharmacol Rev. 2004 Sep;56(3):387-437
pubmed: 15317910
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s
pubmed: 17255300
Clin Cancer Res. 2005 Sep 15;11(18):6634-40
pubmed: 16166442
Tumour Biol. 2016 Sep;37(9):12203-12211
pubmed: 27230680
J Public Health (Oxf). 2019 Nov 28;:
pubmed: 31781767
Int J Mol Sci. 2019 Jan 11;20(2):
pubmed: 30642007
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):147-152
pubmed: 29259292
Cancer Res. 2012 Mar 15;72(6):1407-15
pubmed: 22258454
Hum Reprod. 2007 Jan;22(1):36-44
pubmed: 16905765
Cancer Immunol Res. 2019 Mar;7(3):498-509
pubmed: 30728152
Tumour Biol. 2014 Jul;35(7):7135-45
pubmed: 24760275
Int J Cardiol. 2017 Dec 1;248:394-395
pubmed: 28942879
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
Cancer Res. 2005 Oct 15;65(20):9304-11
pubmed: 16230392
J Cell Physiol. 2018 Apr;233(4):3590-3602
pubmed: 29154474
Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):42-5
pubmed: 26150361
Cancer Sci. 2003 Jul;94(7):618-21
pubmed: 12841871
Nat Med. 2001 Sep;7(9):1048-51
pubmed: 11533709
J Exp Med. 2003 Jan 20;197(2):221-32
pubmed: 12538661
Transplant Res. 2012 Sep 28;1(1):15
pubmed: 23369567
Cancer Res. 2006 Mar 15;66(6):2923-7
pubmed: 16540639
Endocr Relat Cancer. 2015 Aug;22(4):665-78
pubmed: 26113609
Semin Oncol. 2004 Apr;31(2 Suppl 7):22-9
pubmed: 15179621
JGH Open. 2019 Jul 19;4(2):117-125
pubmed: 32280753
Arch Otolaryngol. 1981 Nov;107(11):658-63
pubmed: 7295159
Cancer Causes Control. 2006 Sep;17(7):871-88
pubmed: 16841255
Cancer Causes Control. 2015 Apr;26(4):589-600
pubmed: 25701248
Cancer Immunol Res. 2017 Aug;5(8):695-709
pubmed: 28765120
Dig Dis Sci. 2010 Jun;55(6):1533-9
pubmed: 19672710
Br J Cancer. 2014 Jul 29;111(3):623-7
pubmed: 24945997
Cancer Res. 2019 Apr 15;79(8):1938-1951
pubmed: 30777853
Oncogene. 2006 Nov 9;25(53):7019-28
pubmed: 16732324
Science. 2005 Dec 2;310(5753):1504-10
pubmed: 16293724
J Natl Cancer Inst. 2009 Feb 18;101(4):256-66
pubmed: 19211452
World J Gastroenterol. 2017 Apr 7;23(13):2286-2293
pubmed: 28428708
J Clin Invest. 2014 Nov;124(11):4882-94
pubmed: 25271626
Eur J Surg Oncol. 2003 Mar;29(2):171-7
pubmed: 12633561
J Biol Chem. 2003 Sep 12;278(37):35451-7
pubmed: 12824187
Int J Epidemiol. 2007 Oct;36(5):951-7
pubmed: 17921195
FASEB J. 2007 Aug;21(10):2418-30
pubmed: 17384145
Gastroenterology. 2015 Dec;149(7):1884-1895.e4
pubmed: 26261008
Carcinogenesis. 2007 Mar;28(3):677-84
pubmed: 17052996
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Br J Cancer. 2013 Oct 1;109(7):1921-5
pubmed: 23887604
Biochem Pharmacol. 2010 Sep 15;80(6):838-45
pubmed: 20470757
J Exp Pharmacol. 2012 Aug 10;4:91-6
pubmed: 27186121
Oncotarget. 2018 Nov 20;9(91):36317-36330
pubmed: 30555631
Br J Cancer. 2014 Oct 28;111(9):1852-9
pubmed: 25211662
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
Oncogene. 2006 Sep 7;25(40):5507-16
pubmed: 16607275
Mol Med Rep. 2018 Mar;17(3):4702-4712
pubmed: 29328471
Cancer Prev Res (Phila). 2020 Sep 16;:
pubmed: 32938643
Cancer Res. 2008 May 1;68(9):3251-9
pubmed: 18451151
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
Clin Cancer Res. 2001 Dec;7(12):3971-6
pubmed: 11751489
Cancer Prev Res (Phila). 2011 Aug;4(8):1198-208
pubmed: 21576350
J Leukoc Biol. 1992 Feb;51(2):176-80
pubmed: 1331278
Br J Cancer. 2003 Mar 10;88(5):672-4
pubmed: 12618872
Physiol Rev. 1999 Oct;79(4):1193-226
pubmed: 10508233
Cell Rep. 2017 Oct 3;21(1):154-167
pubmed: 28978469
Gastroenterology. 2011 Feb;140(2):596-607.e7
pubmed: 21070778
Nat Commun. 2020 Jun 12;11(1):2978
pubmed: 32532977
Am J Gastroenterol. 2018 Jun;113(6):845-854
pubmed: 29855546
Br J Cancer. 2012 Jun 26;107(1):207-14
pubmed: 22722313
Adv Biol Regul. 2020 Jan;75:100653
pubmed: 31594701
Br J Pharmacol. 2019 Jun;176(11):1680-1699
pubmed: 30761522
Sci Rep. 2017 Jun 13;7(1):3350
pubmed: 28611431
Cancer Res. 2005 Jun 15;65(12):5211-20
pubmed: 15958566
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12098-102
pubmed: 16880406
Nat Rev Clin Oncol. 2012 Apr 03;9(5):259-67
pubmed: 22473097
PLoS One. 2012;7(7):e40576
pubmed: 22815767
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:383-99
pubmed: 12432931
Cancer Res. 2002 Jan 1;62(1):28-32
pubmed: 11782353
Int J Otolaryngol. 2010;2010:424161
pubmed: 20628564
Mol Med Rep. 2015 Jun;11(6):4454-62
pubmed: 25625500
Breast Cancer Res Treat. 2009 Sep;117(1):141-50
pubmed: 18979210
Int J Cancer. 2009 Jun 1;124(11):2621-33
pubmed: 19235923
N Engl J Med. 2006 Aug 31;355(9):885-95
pubmed: 16943401
Curr Drug Targets. 2019;20(3):302-315
pubmed: 30073924
Oncoimmunology. 2013 Jan 1;2(1):e22647
pubmed: 23482441
Cancer Immunol Immunother. 2020 Dec;69(12):2477-2499
pubmed: 32561967
Br J Pharmacol. 2015 Nov;172(22):5239-50
pubmed: 26377664
Blood. 2003 Sep 15;102(6):1966-77
pubmed: 12791666
Breast Cancer Res Treat. 2010 Oct;123(3):829-36
pubmed: 20697803
Pharmacol Rev. 2007 Sep;59(3):207-24
pubmed: 17878511
J Cell Physiol. 2018 Sep;233(9):6458-6471
pubmed: 29323719
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Cancer Metastasis Rev. 2011 Dec;30(3-4):409-17
pubmed: 22020925
Trends Immunol. 2011 Jan;32(1):19-25
pubmed: 21067974